(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 September 2013 (12.09.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/134743 A9

(51) International Patent Classification:
C07K 16/28 (2006.01) *G01N 33/53* (2006.01)
C07K 16/30 (2006.01) *G01N 33/574* (2006.01)

(21) International Application Number:
PCT/US2013/030055

(22) International Filing Date:
8 March 2013 (08.03.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/685,089 8 March 2012 (08.03.2012) US

(71) Applicant: **HALOZYME, INC.** [US/US]; 11388 Sorrento Valley Road, San Diego, CA 92121 (US).

(72) Inventors: **WEI, Ge**; 11530 Miro Circle, San Diego, CA 92131 (US). **FROST, Gregory**; 13662 Mercado Drive, Del Mar, CA 92014 (US). **HUANG, Lei**; 3683 Caminito Carmel Landing, San Diego, CA 92130 (US). **SHEPARD, H. Michael**; 4637 Pavlov Ave., San Diego, CA 92122 (US). **VAUGHN, Daniel Edward**; 2230 14th St., Encinitas, CA 92024 (US).

(74) Agents: **SEIDMAN, Stephanie L.** et al.; McKENNA LONG & ALDRIDGE LLP, 4435 Eastgate Mall, Suite 400, San Diego, CA 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
24 July 2014

(15) Information about Correction:
see Notice of 24 July 2014

(54) Title: CONDITIONALLY ACTIVE ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.

WO 2013/134743 A9